What is Myasthenia Gravis?
Myasthenia gravis (ORPHA code 589) is a rare autoimmune neuromuscular disorder characterized by fluctuating weakness and fatigue of voluntary muscles. The condition occurs when the body’s immune system attacks the connections between nerves and muscles, specifically targeting acetylcholine receptors at the neuromuscular junction. This disruption prevents proper muscle contraction, leading to progressive weakness that typically worsens with activity and improves with rest. Myasthenia gravis can affect people of any age, though it most commonly develops in women under 40 and men over 60.
Key statistics
| Statistic | Value |
|---|---|
| Global prevalence | 15-20 cases per 100,000 people |
| Annual incidence | 0.5-5 new cases per 100,000 people |
| Peak age of onset | Women: 20-30 years; Men: 50-70 years |
| Mortality rate | Less than 5% with modern treatment |
Symptoms
The hallmark symptoms include muscle weakness, drooping eyelids, double vision, difficulty speaking, trouble swallowing, and fatigue that worsens with activity.
Early symptoms typically begin with the muscles controlling eye and eyelid movement, causing drooping eyelids (ptosis) and double vision (diplopia). These ocular symptoms are present in about 85% of patients and may be the only manifestation for months or years.
Common progressive symptoms include facial muscle weakness leading to difficulty with facial expressions, chewing, and speaking with a nasal quality. Bulbar symptoms such as difficulty swallowing, choking on food or liquids, and slurred speech often develop. Limb weakness typically affects the arms more than legs, causing difficulty lifting objects overhead, climbing stairs, or rising from chairs.
Serious complications can include myasthenic crisis, a life-threatening emergency where respiratory muscles become so weak that mechanical ventilation is required. Crisis affects 15-20% of patients and can be triggered by infections, stress, medications, or surgery.
Causes and risk factors
Myasthenia gravis is primarily an autoimmune condition where the immune system mistakenly produces antibodies against acetylcholine receptors (85% of cases), muscle-specific kinase (MuSK) receptors (5-10% of cases), or other neuromuscular junction proteins. About 10-15% of patients are seronegative, meaning they test negative for known antibodies.
The thymus gland plays a crucial role in the disease development. Approximately 75% of patients have thymic abnormalities, including thymic hyperplasia (65%) or thymomas (10%). The exact trigger for autoimmune activation remains unknown, but genetic predisposition and environmental factors likely contribute.
Risk factors include female gender (2:1 female predominance in early-onset disease), family history of autoimmune diseases, having other autoimmune conditions like thyroid disease or rheumatoid arthritis, and certain medications including antibiotics, beta-blockers, and magnesium.
Prevention
Currently, there is no known way to prevent myasthenia gravis as it is an autoimmune disorder. However, early detection through recognition of characteristic symptoms can lead to prompt treatment and better outcomes. Individuals with family history of autoimmune diseases should be aware of symptoms and seek medical evaluation if muscle weakness develops. Avoiding known trigger medications when possible and maintaining good overall health may help prevent exacerbations in diagnosed patients.
Complications
Without proper treatment, myasthenia gravis can lead to severe disability and life-threatening complications. Myasthenic crisis is the most serious acute complication, occurring in 15-20% of patients and requiring immediate intensive care management.
Long-term complications include chronic respiratory insufficiency, aspiration pneumonia from swallowing difficulties, and progressive muscle atrophy from prolonged weakness. Patients may develop contractures from muscle weakness and experience significant functional disability affecting activities of daily living.
Thymoma-associated myasthenia gravis carries additional risks, as these tumors can be locally invasive and may undergo malignant transformation. Associated autoimmune conditions occur in 10-15% of patients, including thyroid disorders, diabetes mellitus, and other autoimmune diseases.
Diagnosis
Diagnosis relies on clinical presentation, specialized testing, and response to treatment. The diagnostic workup includes the edrophonium (Tensilon) test, where short-acting anticholinesterase medication temporarily improves muscle weakness. However, this test is less commonly used due to safety concerns.
Blood tests measure specific antibodies including acetylcholine receptor antibodies (positive in 85% of generalized cases), muscle-specific kinase (MuSK) antibodies, and lipoprotein-related protein 4 (LRP4) antibodies. Repetitive nerve stimulation studies show characteristic decremental response, while single-fiber electromyography demonstrates increased jitter and blocking.
Imaging studies include chest CT or MRI to evaluate the thymus gland for hyperplasia or thymoma. All patients should undergo thymic imaging as part of the initial evaluation. Additional testing may include pulmonary function tests to assess respiratory muscle strength and ice pack tests for ptosis.
Treatment
Treatment approaches include symptomatic therapy, immunosuppression, and surgical intervention. Pyridostigmine, an acetylcholinesterase inhibitor, provides symptomatic relief by increasing acetylcholine availability at the neuromuscular junction.
Immunosuppressive therapy forms the cornerstone of treatment. Prednisone is typically the first-line immunosuppressant, often combined with steroid-sparing agents such as azathioprine, mycophenolate mofetil, or methotrexate.
For refractory cases, newer immunotherapies include rituximab, eculizumab (an orphan drug specifically approved for refractory generalized myasthenia gravis), and efgartigimod, a novel FcRn antagonist.
Thymectomy is recommended for patients with thymoma and considered for patients under 65 with generalized disease. Plasmapheresis and intravenous immunoglobulin provide rapid improvement during crisis or before surgery.
Prognosis
With modern treatment, the prognosis for myasthenia gravis has dramatically improved. Most patients achieve good disease control and maintain near-normal life expectancy. Approximately 10-20% of patients may achieve complete remission, particularly those with early-onset disease who undergo thymectomy.
Without treatment, the condition typically progresses from ocular to generalized weakness, with significant morbidity and mortality. The mortality rate has decreased from 30-40% historically to less than 5% with current management. However, myasthenic crisis still carries a mortality risk of 3-5% despite intensive care treatment.
Factors associated with better prognosis include younger age at onset, purely ocular disease, and early thymectomy. Patients with MuSK-positive disease may have a more severe course but can still achieve good outcomes with appropriate treatment.
Quality of life
Living with myasthenia gravis requires significant lifestyle adaptations and ongoing medical management. Patients should maintain regular sleep schedules, as fatigue can worsen symptoms. Energy conservation techniques, including pacing activities and taking frequent rest breaks, help manage daily tasks.
Dietary modifications may be necessary for those with swallowing difficulties. Soft, easily chewable foods and thickened liquids can reduce aspiration risk. Some patients benefit from eating smaller, more frequent meals to avoid fatigue during eating.
Exercise should be tailored to individual capabilities, focusing on maintaining muscle strength without causing excessive fatigue. Physical therapy can help optimize function and prevent complications. Mental health support is crucial, as the unpredictable nature of symptoms can lead to anxiety and depression.
Workplace accommodations may include flexible scheduling, ergonomic workstations, and modified duties during flares. Educational institutions should provide similar accommodations for students, including extended test time and note-taking assistance.
Pregnancy and fertility
Myasthenia gravis can affect pregnancy outcomes and requires specialized management. The condition may worsen during pregnancy in 30-40% of women, remain stable in 30%, or improve in 30%. Symptoms often fluctuate throughout pregnancy and may worsen in the postpartum period.
Medication management during pregnancy requires careful consideration. Pyridostigmine is generally safe during pregnancy, while corticosteroids may be used when necessary. Many immunosuppressive medications require modification or discontinuation.
Neonatal myasthenia gravis occurs in 10-20% of infants born to mothers with the condition due to maternal antibody transfer. This typically resolves within 2-3 weeks as maternal antibodies clear from the infant’s system. Close monitoring of newborns is essential for respiratory and feeding difficulties.
Fertility is generally not affected by myasthenia gravis itself, though medications may have reproductive effects that should be discussed with healthcare providers before conception.
Children
Pediatric myasthenia gravis can be congenital or acquired. Congenital myasthenic syndromes are rare genetic disorders affecting the neuromuscular junction, while juvenile myasthenia gravis is autoimmune and similar to adult-onset disease.
Children with myasthenia gravis may experience delayed motor development, difficulty with physical activities, and academic challenges due to fatigue. School accommodations should include rest periods, modified physical education, and awareness among teachers about the condition’s fluctuating nature.
Growth and development are typically normal with proper treatment, though chronic corticosteroid use may affect growth velocity. Regular monitoring by pediatric specialists is essential for optimal outcomes.
Transition to adult care should begin in adolescence, with gradual transfer of disease management knowledge and responsibilities to the patient.
When to see a doctor
Immediate medical attention is required for signs of myasthenic crisis, including severe difficulty breathing, inability to swallow, or significant worsening of weakness. These symptoms constitute a medical emergency requiring hospital evaluation.
Urgent care should be sought for new respiratory symptoms, significant changes in voice or swallowing, or sudden worsening of muscle weakness that interferes with daily activities. Patients should also contact healthcare providers before starting new medications, as many drugs can worsen myasthenic symptoms.
Routine follow-up appointments are essential for monitoring disease progression, adjusting medications, and screening for complications. Annual evaluations should include assessment of symptom control, medication side effects, and functional status.
Regional context
Limited data exists specifically for myasthenia gravis prevalence in the Caucasus region. However, studies from neighboring regions suggest similar prevalence rates to global averages. Access to specialized neuromuscular care and advanced treatments may vary across the region, with major medical centers in Tbilisi, Yerevan, and Baku offering more comprehensive services.
Regional researchers have contributed to understanding genetic factors in autoimmune diseases, though specific studies on myasthenia gravis in Caucasus populations are limited. GMJ welcomes contributions from regional researchers to build the evidence base for myasthenia gravis in the Caucasus.
Research and clinical trials
Current research focuses on developing targeted therapies, improving understanding of disease mechanisms, and identifying biomarkers for treatment response. Novel treatments under investigation include complement inhibitors, B-cell targeting therapies, and neonatal Fc receptor antagonists.
Recent breakthroughs include the approval of efgartigimod and eculizumab for refractory disease. Gene therapy approaches and precision medicine strategies based on antibody profiles are emerging areas of research.
Patients interested in clinical trials can search ClinicalTrials.gov for current studies. Participation in research helps advance understanding and treatment of this rare condition.
Frequently asked questions
Is myasthenia gravis hereditary?
Most cases are not directly inherited, though there may be genetic predisposition to autoimmune diseases. Congenital myasthenic syndromes are rare inherited forms affecting the neuromuscular junction.
Can myasthenia gravis be cured?
While there is no cure, most patients achieve good symptom control with treatment. Some patients may achieve remission, particularly with early diagnosis and appropriate therapy including thymectomy.
Will I need to take medication forever?
Most patients require long-term treatment, though medication regimens may be adjusted over time. Some patients may achieve remission allowing medication reduction or discontinuation under medical supervision.
Can I exercise with myasthenia gravis?
Yes, but exercise should be tailored to avoid excessive fatigue. Low-impact activities and strength training with appropriate rest periods are generally beneficial when done under professional guidance.
How quickly does myasthenia gravis progress?
Disease progression varies significantly. Some patients have stable ocular symptoms for years, while others develop generalized weakness within months. Early treatment can help prevent progression.
Support and resources
International organizations:
– Myasthenia Gravis Foundation of America (myasthenia.org)
– International Association of Gerontology and Geriatrics
– Orphanet (orpha.net) – ORPHA code 589
– EURORDIS (eurordis.org) – European rare disease organization
– NORD – National Organization for Rare Disorders (rarediseases.org)
Medical resources:
– World Health Organization (who.int)
– GeneReviews (ncbi.nlm.nih.gov/books/NBK1408/)
– Cochrane Library for evidence-based treatment reviews
Related conditions
Lambert-Eaton Myasthenic Syndrome – Another autoimmune neuromuscular junction disorder affecting presynaptic acetylcholine release, often associated with small cell lung cancer.
Congenital Myasthenic Syndromes – Rare inherited disorders affecting various components of the neuromuscular junction, present from birth with muscle weakness.
Inflammatory Myopathies – Group of muscle diseases including polymyositis and dermatomyositis that can present with similar weakness patterns.
Motor Neuron Disease – Progressive neurodegenerative disorders affecting motor neurons, including ALS, which can initially mimic myasthenia gravis.
Thyroid Eye Disease – Autoimmune condition affecting eye muscles that can cause similar ocular symptoms to myasthenia gravis.
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.
Cite this page
GMJ News Desk. “Myasthenia Gravis.” GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/condition/myasthenia-gravis/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?